Stockreport

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem, Inc.  (VSTM) 
Last verastem, inc. earnings: 10/29 04:17 pm Check Earnings Report
US:NASDAQ Investor Relations: verastem.com
PDF BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven [Read more]